{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:04Z","timestamp":1777876804176,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"national science and technology council","award":["MOST 1112314B037070MY3"],"award-info":[{"award-number":["MOST 1112314B037070MY3"]}]},{"name":"national science and technology council","award":["NSTC 1122314B037050MY3"],"award-info":[{"award-number":["NSTC 1122314B037050MY3"]}]},{"name":"national science and technology council","award":["NSTC 1132321B037006"],"award-info":[{"award-number":["NSTC 1132321B037006"]}]},{"name":"national science and technology council","award":["NSTC 1132314B037057"],"award-info":[{"award-number":["NSTC 1132314B037057"]}]},{"name":"national science and technology council","award":["NSTC 1142314B037103MY3"],"award-info":[{"award-number":["NSTC 1142314B037103MY3"]}]},{"name":"national science and technology council","award":["NSTC 1142321B037003"],"award-info":[{"award-number":["NSTC 1142321B037003"]}]},{"name":"ministry of health and welfare","award":["MOHW113TDUB222134014"],"award-info":[{"award-number":["MOHW113TDUB222134014"]}]},{"DOI":"10.13039\/501100004694","name":"the Kaohsiung Medical University Hospital","doi-asserted-by":"crossref","award":["KMUH1122R37"],"award-info":[{"award-number":["KMUH1122R37"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004694","name":"the Kaohsiung Medical University Hospital","doi-asserted-by":"crossref","award":["KMUH1122R38"],"award-info":[{"award-number":["KMUH1122R38"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004694","name":"the Kaohsiung Medical University Hospital","doi-asserted-by":"crossref","award":["KMUH1122R39"],"award-info":[{"award-number":["KMUH1122R39"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004694","name":"the Kaohsiung Medical University Hospital","doi-asserted-by":"crossref","award":["KMUH1122M27"],"award-info":[{"award-number":["KMUH1122M27"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1122M28"],"award-info":[{"award-number":["KMUH1122M28"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1122M29"],"award-info":[{"award-number":["KMUH1122M29"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1133R31"],"award-info":[{"award-number":["KMUH1133R31"]}]},{"name":"Kaohsiung Medical University Research Center","award":["KMUTC113A04"],"award-info":[{"award-number":["KMUTC113A04"]}]},{"name":"National Tsing Hua UniversityKaohsiung Medical University","award":["NTHUKMUKT114P008"],"award-info":[{"award-number":["NTHUKMUKT114P008"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1133R32"],"award-info":[{"award-number":["KMUH1133R32"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1133R33"],"award-info":[{"award-number":["KMUH1133R33"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1133M58"],"award-info":[{"award-number":["KMUH1133M58"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH1133M59"],"award-info":[{"award-number":["KMUH1133M59"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUHS11303"],"award-info":[{"award-number":["KMUHS11303"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUHSH11309"],"award-info":[{"award-number":["KMUHSH11309"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUHSH11327"],"award-info":[{"award-number":["KMUHSH11327"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Regorafenib targets tumor angiogenesis and oncogenic signaling by inhibiting multiple kinases involved in angiogenesis, oncogenesis, and the tumor microenvironment. Chemotherapy of FOLFIRI causes direct cytotoxic damage to tumor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      We evaluated the efficacy and safety of regorafenib plus FOLFIRI with\n                      <jats:italic toggle=\"yes\">uridine diphosphate glucuronosyltransferase 1A1<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">UGT1A1<\/jats:italic>\n                      ) genotyping-guided irinotecan dose escalation in patients with metastatic colorectal cancer (mCRC) who had received second- or third-line systemic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A total of 153 patients were randomized (at a ratio of 2:1) to receive either regorafenib plus FOLFIRI (experimental group, 102 patients) or regorafenib alone (control group, 51 patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Both groups received regorafenib (120\u2009mg daily) for 21 consecutive days in 28-day cycles. In addition, the experimental group received FOLFIRI with\n                      <jats:italic toggle=\"yes\">UGT1A1<\/jats:italic>\n                      genotyping-guided irinotecan dose escalation. The primary outcome was progression-free survival (PFS). The secondary outcomes were overall survival (OS), disease control rate (DCR), and adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The final cohort included 116 patients. The experimental group exhibited significant improvement in PFS (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.016) but marginally significant improvements in DCR (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.055). Specifically, PFS improved significantly for experimental group patients carrying wild-type\n                      <jats:italic toggle=\"yes\">rat sarcoma virus<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">RAS; p<\/jats:italic>\n                      \u2009=\u20090.003) and those carrying left-sided colon tumors (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.015). A trend toward improved OS was noted in experimental group patients carrying wild-type\n                      <jats:italic toggle=\"yes\">RAS<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.096). No significant between-group difference was observed in the incidence of severe adverse events (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that regorafenib plus FOLFIRI significantly improved PFS in patients with mCRC and offers a safety profile similar to that of regorafenib alone. This regimen may be particularly beneficial for patients with mCRC carrying wild-type\n                      <jats:italic toggle=\"yes\">RAS<\/jats:italic>\n                      and those carrying left-sided tumors. However, larger phase III randomized controlled trials are necessary to confirm the efficacy and safety of this combination therapy before adoption into standard practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov registry: NCT03880877 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/search?cond=NCT03880877\">https:\/\/clinicaltrials.gov\/search?cond=NCT03880877<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251371489","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:28:10Z","timestamp":1761204490000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of regorafenib plus FOLFIRI with\n                    <i>UGT1A1<\/i>\n                    genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter, phase II, open-label, two-arm randomized controlled tria"],"prefix":"10.1177","volume":"17","author":[{"given":"Ching-Wen","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao-Wei","family":"Ker","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tainan Municipal Hospital (Managed by Show Chwan Care Corporation), Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Kun","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Surgery, Faculty of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chih","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Surgery, Faculty of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Jung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang-Lin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-2621","authenticated-orcid":false,"given":"Jaw-Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100 Tzyou 1st Road, Kaohsiung 807, Taiwan"},{"name":"Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0076-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq222"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7147"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1193"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.08.002"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2188195"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0938-y"},{"issue":"10","key":"e_1_3_4_10_2","first-page":"896","volume":"26","author":"FDA approves regorafenib (Stivarga) for metastatic colorectal cancer","year":"2012","unstructured":"FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 2012; 26(10): 896.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_4_11_2","first-page":"2143","article-title":"FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping","volume":"7","author":"Lu C-Y","year":"2014","unstructured":"Lu C-Y, Yeh Y-S, Huang C-W, et al. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 2014; 7: 2143\u20132146.","journal-title":"Onco Targets Ther"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.12.015"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.0314"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.031"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.12.009"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3727\/97818823455816X14786040691928"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.12.003"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3917-z"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_22_2","unstructured":"EQUATOR Network. Guidelines for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension https:\/\/www.equator-network.org\/reporting-guidelines\/guidelines-for-reporting-outcomes-in-trial-protocol-the-spirit-outcomes-2022-extension\/ (2022 accessed 18 June 2025)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00353-4"},{"key":"e_1_3_4_24_2","first-page":"6333","article-title":"Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry","volume":"13","author":"Chen C-C","year":"2023","unstructured":"Chen C-C, Chang S-C, Chang Y-Y, et al. Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry. Am J Cancer Res 2023; 13: 6333\u20136345.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-3539"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14974"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0458-1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.015"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S38335"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2016-134547"},{"key":"e_1_3_4_31_2","article-title":"A phase II study of regorafenib with a lower starting dose in patients with metastatic colorectal cancer: exposure-toxicity analysis of\u2009unbound regorafenib and its active metabolites (RESET trial)","volume":"19","author":"Suzuki T","year":"2020","unstructured":"Suzuki T, Sukawa Y, Imamura CK, et al. A phase II study of regorafenib with a lower starting dose in patients with metastatic colorectal cancer: exposure-toxicity analysis of\u2009unbound regorafenib and its active metabolites (RESET trial). Clin Colorectal Cancer 2020; 19: 13\u201321.e3.","journal-title":"Clin Colorectal Cancer"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0278"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt056"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31552"},{"key":"e_1_3_4_35_2","article-title":"Combination chemotherapy with regorafenib in metastatic colorectal cancer treatment: a single center, retrospective study","volume":"13","author":"Lin C-Y","year":"2018","unstructured":"Lin C-Y, Lin T-H, Chen C-C, et al. Combination chemotherapy with regorafenib in metastatic colorectal cancer treatment: a single center, retrospective study. PLoS One 2018; 13: e0190497.","journal-title":"PLoS One"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29106"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251371489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251371489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251371489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:16Z","timestamp":1777588396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251371489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"alternative-id":["10.1177\/17588359251371489"],"URL":"https:\/\/doi.org\/10.1177\/17588359251371489","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251371489"}}